Metabolic alterations and hepatitis C: From bench to bedside

Area of Science:

• Hepatology
• Virology
• Metabolic Syndrome

Background:

• Hepatitis C virus (HCV) infection is associated with various metabolic disorders, including hypolipidemia, hepatic steatosis, insulin resistance, metabolic syndrome, and diabetes.
• HCV's life cycle relies on host cholesterol metabolism, with viral proteins perturbing key lipid and glucose pathways.
• While mouse models show metabolic changes, their complete relevance to human HCV infection is uncertain.

Purpose of the Study:

• To provide a comprehensive overview of metabolic and adipocytokine alterations in patients with chronic hepatitis C (CHC).
• To examine the relationship between HCV infection, metabolic dysfunction, and cardiovascular events.
• To highlight the impact of anti-HCV therapy on metabolic health.

Main Methods:

• Review of cross-sectional and longitudinal cohort studies on CHC patients.
• Analysis of data on metabolic alterations, cardiovascular events, and adipocytokine changes.
• Consideration of confounders like HCV genotype and baseline glucose metabolism.

Main Results:

• Cross-sectional studies show increased prevalence of metabolic alterations and cardiovascular events in CHC patients, though results vary.
• Longitudinal studies indicate that viral clearance via anti-HCV therapy favorably impacts metabolic alterations and cardiovascular risks.
• Data on HCV infection and adipocytokine alterations remain inconclusive.

Conclusions:

• HCV infection contributes to significant metabolic disturbances and increased cardiovascular risk.
• Anti-HCV therapy demonstrates a beneficial effect on metabolic health and cardiovascular outcomes.
• Further research is needed to fully understand HCV-associated metabolic changes and adipocytokine alterations, especially considering confounders.